Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by Pandoraon Jun 21, 2022 12:30pm
155 Views
Post# 34771597

RE:RE:RE:RE:RE:RE:RE:RE:RE:new tweet from SBM

RE:RE:RE:RE:RE:RE:RE:RE:RE:new tweet from SBM
MirrorWorldMan wrote: It is difficult to understand why Howie wants to still to business with Wannabang,  Afterall, it took 10 years to do anything with our SGLT2 and then that company dumped us for generics.  They must of know of the pending favourable generic government policies and strung us along.  Now they are saying we go to pets.  Whats stopping anyone from using a generic SGLT2 in pets as well.  I would dump them as they dump us.  Businesses are moving out of China now into more favourable EU manufacturing enviroments  and Howie wants to continue with a company proven to abrasive to our needs?  Crazy


From that April update:

"The combined scientific knowledge of Sirona and Wanbang will significantly increase the speed to commercialization of TFC-039. This includes extensive data, advanced manufacturing process development and the ability to commercially manufacture TFC-039. The new agreement was a desired step on the part of the interested partners to create the legal framework and to have certainty regarding production capacities and costs. Now that this has been finalized, the probability of a successful licensing agreement in the near future has been made much stronger.

This LOI is a modification of a previous agreement signed February 8th, 2021 which was mentioned in the CEO Update of 24 February 2021.  The agreement will focus solely on applying TFC-039 to animal health.

Studies on a new indication for TFC-039 are also ongoing. Details of the new indication cannot be disclosed, but the opportunity as a valuable therapeutic exists and is an area of great need."



<< Previous
Bullboard Posts
Next >>